ANI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
February 29, 2024 at 07:23 am EST
Share
ANI Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 486.82 million compared to USD 316.39 million a year ago. Net income was USD 18.78 million compared to net loss of USD 47.9 million a year ago.
Basic earnings per share from continuing operations was USD 0.86 compared to basic loss per share from continuing operations of USD 3.05 a year ago. Diluted earnings per share from continuing operations was USD 0.85 compared to diluted loss per share from continuing operations of USD 3.05 a year ago.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
ANI PHARMACEUTICALS, INC. 
